Customizing G Protein-coupled receptor models for structure-based virtual screening.
暂无分享,去创建一个
[1] D. Rognan,et al. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.
[2] Didier Rognan,et al. Positive and Negative Allosteric Modulators of the Ca2+-sensing Receptor Interact within Overlapping but Not Identical Binding Sites in the Transmembrane Domain* , 2004, Journal of Biological Chemistry.
[3] R. Wong,et al. Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors , 2008, Molecular Pharmacology.
[4] Krzysztof Palczewski,et al. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin , 2006, Proceedings of the National Academy of Sciences.
[5] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[6] Ajay N. Jain. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..
[7] Arthur Christopoulos,et al. A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.
[8] A. Smolyar,et al. Static and dynamic roles of extracellular loops in G-protein-coupled receptors: a mechanism for sequential binding of thyrotropin-releasing hormone to its receptor. , 1998, Biophysical journal.
[9] Patrick Scheerer,et al. Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.
[10] P. Malherbe,et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. , 2003, Molecular pharmacology.
[11] D. Rognan,et al. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.
[12] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[13] Stefano Costanzi,et al. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.
[14] H. Kikkawa,et al. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. , 1998, Molecular pharmacology.
[15] D. Robertson,et al. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. , 2000, Journal of medicinal chemistry.
[16] Rolf Apweiler,et al. Evaluation of methods for the prediction of membrane spanning regions , 2001, Bioinform..
[17] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[18] Yu Zhang,et al. Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly , 2008, Molecules.
[19] Antti Poso,et al. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. , 2005, Journal of medicinal chemistry.
[20] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[21] Olga Yuzlenko,et al. Molecular modeling of A1 and A2A adenosine receptors: Comparison of rhodopsin‐ and β2‐adrenergic‐based homology models through the docking studies , 2009, J. Comput. Chem..
[22] R. Stevens,et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.
[23] Sid Topiol,et al. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.
[24] M Stahl,et al. Development of filter functions for protein-ligand docking. , 1998, Journal of molecular graphics & modelling.
[25] P. Newham,et al. The orphan G-protein coupled receptor RDC1: evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover. , 2006, Osteoarthritis and cartilage.
[26] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[27] B. Kobilka. Agonist binding: a multistep process. , 2004, Molecular pharmacology.
[28] Fred E. Cohen,et al. Automated extraction of mutation data from the literature: application of MuteXt to G protein-coupled receptors and nuclear hormone receptors , 2004, Bioinform..
[29] Axel L. Dessal,et al. G protein betagamma subunits as targets for small molecule therapeutic development. , 2008, Combinatorial chemistry & high throughput screening.
[30] Chris G. Kruse,et al. Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.
[31] J. Ballesteros,et al. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. , 2002, The Journal of biological chemistry.
[33] Thomas Lengauer,et al. Flexible docking under pharmacophore type constraints , 2002, J. Comput. Aided Mol. Des..
[34] I. Muegge. Selection criteria for drug‐like compounds , 2003, Medicinal research reviews (Print).
[35] J. Vilardaga,et al. Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality☆ , 1999, Peptides.
[36] K. Jacobson,et al. Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. , 1997, Journal of medicinal chemistry.
[37] D. Hay,et al. A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors. , 2005, Molecular pharmacology.
[38] K. Adachi,et al. Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. , 2005, Bioorganic & medicinal chemistry.
[39] Didier Rognan,et al. Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.
[40] D. Grigoriadis,et al. Corrigendum to “1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: Novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF1) receptor antagonist activities” [Bioorg. Med. Chem. Lett. 11 (2001) 3165–3168] , 2010 .
[41] Krzysztof Palczewski,et al. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. , 2003, Biochemistry.
[42] Andreas Mühlemann,et al. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. , 2006, European journal of pharmacology.
[43] Duan Yang,et al. The evolution of transmembrane helix kinks and the structural diversity of G protein-coupled receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] Didier Rognan,et al. A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.
[45] Jun Zhang,et al. Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists , 2008, Molecular Pharmacology.
[46] H. Khorana,et al. Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.
[47] Z. Deng,et al. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.
[48] Pedro Alexandrino Fernandes,et al. Protein–ligand docking: Current status and future challenges , 2006, Proteins.
[49] Thomas Lengauer,et al. Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.
[50] C. Hodge,et al. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies. , 1999, Journal of medicinal chemistry.
[51] Martin Stahl,et al. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP , 2006, Journal of neurochemistry.
[52] S. Betz,et al. Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor. , 2006, Biochemical pharmacology.
[53] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.
[54] Leonardo Pardo,et al. Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity. , 2007, Current topics in medicinal chemistry.
[55] J. Ballesteros,et al. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.
[56] Peter L. Freddolino,et al. Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. IJzerman,et al. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[58] Y. Fujiwara,et al. Identification of the Hydrophobic Ligand Binding Pocket of the S1P1 Receptor* , 2007, Journal of Biological Chemistry.
[59] O. Lichtarge,et al. Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. , 1999, The Journal of biological chemistry.
[60] Didier Rognan,et al. Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..
[61] J. Ballesteros,et al. The Forgotten Serine , 2000, The Journal of Biological Chemistry.
[62] E. Kellenberger,et al. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. , 2007, Journal of medicinal chemistry.
[63] F. Gasparini,et al. The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.
[64] Béla Noszál,et al. Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. , 2008, European journal of medicinal chemistry.
[65] Antti Poso,et al. Development of a 3D model for the human cannabinoid CB1 receptor. , 2004, Journal of medicinal chemistry.
[66] J. Wess,et al. Site-directed Mutagenesis Identifies Residues Involved in Ligand Recognition in the Human A2a Adenosine Receptor (*) , 1995, The Journal of Biological Chemistry.
[67] D. Rognan,et al. Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor* , 2003, Journal of Biological Chemistry.
[68] L. Pardo,et al. Linking agonist binding to histamine H1 receptor activation , 2005, Nature chemical biology.
[69] J. Kew,et al. Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.
[70] Shay Bar-Haim,et al. G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[71] B Fischer,et al. Receptor flexibility for large-scale in silico ligand screens: chances and challenges. , 2008, Methods in molecular biology.
[72] J. Jameson,et al. Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. , 2001, The Journal of clinical endocrinology and metabolism.
[73] T. Okada,et al. Local peptide movement in the photoreaction intermediate of rhodopsin , 2006, Proceedings of the National Academy of Sciences.
[74] S. A. Parent,et al. Identification of Leu276 of the S1P1 Receptor and Phe263 of the S1P3 Receptor in Interaction with Receptor Specific Agonists by Molecular Modeling, Site-Directed Mutagenesis, and Affinity Studies , 2007, Molecular Pharmacology.
[75] B. Kobilka,et al. New G-protein-coupled receptor crystal structures: insights and limitations. , 2008, Trends in pharmacological sciences.
[76] T. Schwartz,et al. Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8 , 2007, Molecular Pharmacology.
[77] Didier Rognan,et al. Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..
[78] Christopher A Reynolds,et al. Toward the active conformations of rhodopsin and the β2‐adrenergic receptor , 2004, Proteins.
[79] C. Altenbach,et al. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation , 2008, Proceedings of the National Academy of Sciences.
[80] J. Wess,et al. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.
[81] C. Strader,et al. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.
[82] M. Wheeler,et al. Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. , 1997, Molecular endocrinology.
[83] Stefano Costanzi,et al. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.
[84] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[85] G. Klebe,et al. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. , 2003, Journal of molecular biology.
[86] U. Gether. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.
[87] A. Parrill,et al. A Single Amino Acid Determines Lysophospholipid Specificity of the S1P1 (EDG1) and LPA1 (EDG2) Phospholipid Growth Factor Receptors* , 2001, The Journal of Biological Chemistry.
[88] Gert Vriend,et al. GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..
[89] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[90] Sebastian Radestock,et al. Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..
[91] G Vriend,et al. Modeling GPCRs. , 2006, Ernst Schering Foundation symposium proceedings.
[92] E. Jaeger,et al. Comparison of automated docking programs as virtual screening tools. , 2005, Journal of Medicinal Chemistry.
[93] M. Fan,et al. Transmembrane Residues of the Parathyroid Hormone (PTH)/PTH-related Peptide Receptor That Specifically Affect Binding and Signaling by Agonist Ligands* , 1996, The Journal of Biological Chemistry.
[94] J. Wess,et al. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. , 1996, Molecular pharmacology.
[95] Stefano Costanzi,et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.
[96] D. E. Clark,et al. A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor. , 2004, Journal of medicinal chemistry.
[97] Nagarajan Vaidehi,et al. Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. , 2008, Biophysical journal.
[98] A. Parrill. Lysophospholipid interactions with protein targets. , 2008, Biochimica et biophysica acta.
[99] Didier Rognan,et al. High‐Throughput Modeling of Human G‐Protein Coupled Receptors: Amino Acid Sequence Alignment, Three‐Dimensional Model Building, and Receptor Library Screening. , 2004 .
[100] D. Flower,et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination , 2008, Proceedings of the National Academy of Sciences.
[101] T. Frimurer,et al. Structure of the integral membrane domain of the GLP1 receptor , 1999, Proteins.
[102] M. Greenwood,et al. Physiological relevance of GPCR oligomerization and its impact on drug discovery. , 2008, Drug discovery today.
[103] Garland R Marshall,et al. Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. , 2008, Journal of medicinal chemistry.
[104] Junmei Wang,et al. GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..
[105] Mayako Michino,et al. Improved model building and assessment of the Calcium‐sensing receptor transmembrane domain , 2008, Proteins.
[106] Thomas Lengauer. Bioinformatics - From Genomes to Therapies - Introduction , 2007 .
[107] G. Vigers,et al. Multiple active site corrections for docking and virtual screening. , 2004, Journal of medicinal chemistry.
[108] Claudio N. Cavasotto,et al. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.
[109] Jürgen Bajorath,et al. Virtual screening methods that complement HTS. , 2004, Combinatorial chemistry & high throughput screening.
[110] Béla Noszál,et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. , 2008, Journal of medicinal chemistry.
[111] Thierry Langer,et al. Pharmacophores and Pharmacophore Searches: LANGER: PHARMACOPHORES AND PHARMACOPHORE SEARCHES O-BK , 2006 .
[112] Gilles Marcou,et al. Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..
[113] T. Schwartz,et al. Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.
[114] Kenneth Jones,et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.
[115] C. Strader,et al. Identification of residues required for ligand binding to the beta-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[116] Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. , 1997, Molecular endocrinology.
[117] Shoshana J. Wodak,et al. Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3* , 2003, The Journal of Biological Chemistry.
[118] Raphael Nudelman,et al. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. , 2006, Journal of medicinal chemistry.
[119] Robert P Bywater,et al. Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.
[120] Oliver P. Ernst,et al. Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.
[121] B. Kobilka,et al. Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. , 1993, Molecular pharmacology.
[122] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.
[123] Didier Rognan,et al. Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..
[124] Richard D. Taylor,et al. Virtual Screening Using Protein—Ligand Docking: Avoiding Artificial Enrichment. , 2004 .
[125] D. Langley,et al. Expanding GPCR homology model binding sites via a balloon potential: A molecular dynamics refinement approach , 2008, Proteins.
[126] Kurt Kristiansen,et al. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.
[127] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[128] Julian Tirado-Rives,et al. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. , 2006, Journal of medicinal chemistry.
[129] T. A. Norris,et al. Molecular Modeling: Basic Principles and Applications H.-D. Höltje and G. Folkers pp. XII + 194, ISBN 3-527-29384-1 , 1999 .
[130] Ola Engkvist,et al. Molecular modeling of the second extracellular loop of G‐protein coupled receptors and its implication on structure‐based virtual screening , 2008, Proteins.
[131] David E. Gloriam,et al. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. , 2006, Genomics.
[132] Didier Rognan,et al. ConsDock: A new program for the consensus analysis of protein–ligand interactions , 2002, Proteins.
[133] Leonardo Pardo,et al. An Activation Switch in the Rhodopsin Family of G Protein-coupled Receptors , 2005, Journal of Biological Chemistry.
[134] Xueliang Fang,et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.
[135] Vadim Cherezov,et al. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.
[136] Tsutomu Kouyama,et al. Crystal structure of squid rhodopsin , 2008, Nature.
[137] R. J. Bailey,et al. Agonist‐dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor , 2007, British journal of pharmacology.
[138] D. Hurst,et al. Cysteine 2.59(89) in the Second Transmembrane Domain of Human CB2 Receptor Is Accessible within the Ligand Binding Crevice: Evidence for Possible CB2 Deviation from a Rhodopsin Template , 2005, Molecular Pharmacology.
[139] Gilles Marcou,et al. Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..
[140] Gilles Labesse,et al. Common Structural Requirements for Heptahelical Domain Function in Class A and Class C G Protein-coupled Receptors* , 2007, Journal of Biological Chemistry.
[141] L. Pardo,et al. Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine(1a) receptor ligands to explore the three-dimensional structure of the receptor. , 2002, Molecular pharmacology.
[142] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[143] T K Attwood,et al. A compendium of specific motifs for diagnosing GPCR subtypes. , 2001, Trends in pharmacological sciences.
[144] Maya Topf,et al. PREDICT modeling and in‐silico screening for G‐protein coupled receptors , 2004, Proteins.
[145] H. Schiöth,et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.
[146] Manfred Burghammer,et al. Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.
[147] D. Grigoriadis,et al. 1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF(1)) receptor antagonist activities. , 2001, Bioorganic & medicinal chemistry letters.
[148] J. Ballesteros,et al. Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.
[149] Gerhard Hessler,et al. Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.
[150] Marcus Elstner,et al. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.
[151] O. Civelli,et al. Orphan GPCR research , 2008, British journal of pharmacology.
[152] C. Strader,et al. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.
[153] Tudor I. Oprea,et al. Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.
[154] Christopher R. Corbeil,et al. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go , 2008, British journal of pharmacology.
[155] Brian Hudson,et al. Strategic Pooling of Compounds for High-Throughput Screening , 1999, J. Chem. Inf. Comput. Sci..
[156] Didier Rognan,et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.
[157] W. Spooren,et al. Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure. , 2007, Bioorganic & medicinal chemistry letters.
[158] B. Raaka,et al. Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. , 2007, Journal of medicinal chemistry.